Abstract:The EGFR family play a significant role in cell signal transduction and their overexpression is implicated in the pathogenesis of numerous human solid cancers. Inhibition of the EGFR-mediated signaling pathways by EGFR inhibitors is a widely used strategy for the treatment of cancers. In most cases, the EGFR inhibitors used in clinic were only effective when the cancer cells harbored specific activating EGFR mutations which appeared to preserve the ligand-dependency of receptor activation but altered the pattern of downstream signaling pathways. Moreover, cancer is a kind of multifactorial disease, and therefore manipulating a single target may result in treatment failure. Although drug combinations for the treatment of cancers proved to be successful, the use of two or more drugs concurrently still was a challenge in clinical therapy owing to various dose-limiting toxicities and drug-drug interactions caused by pharmacokinetic profiles changed. Therefore, a single drug targeting two or multiple targets could serve as an effective strategy for the treatment of cancers. In recent, drugs with diverse pharmacological effects have been shown to be more advantageous than combination therapies due to their lower incidences of side effects and more resilient therapies. Accordingly, dual target-single-agent strategy has become a popular field for cancer treatment, and researchers became more and more interest in the development of novel dual-target drugs in recent years. In this review, we briefly introduce the EGFR family proteins and synergisms between EGFR and other anticancer targets, and summarizes the development of potential dual target inhibitors based on wild-type and/or mutant EGFR for the treatment of solid cancers in the past five years. Additionally, the rational design and SARs of these dual target agents are also presented in detailed, which will lay a significant foundation for the further development of novel EGFR-based dual inhibitors with excellent druggability.

Multitarget Inhibitors Derived from Crosstalk Mechanism Involving VEGFR2.

Clinical development of dual tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor and platelet- derived growth factor receptor

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy

Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.

Development of Egfr Family Small Molecule Inhibitors for Anticancer Intervention: an Overview of Approved Drugs and Clinical Candidates

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Antiangiogenic therapy: how far is it to upgrade?

Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents

Research Progress in Quinazoline Derivatives As Multi-Target Tyrosine Kinase Inhibitors

Therapeutic Paradigm Of Dual Targeting Vegf And Pdgf For Effectively Treating Fgf-2 Off-Target Tumors

Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis

Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review

Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions